A multi-centre, randomised, double-blind active controlled study to compare the effect of 24 weeks treatment with combination therapy of LAF237 [vildagliptin] and pioglitazone to LAF237 monotherapy or pioglitazone monotherapy [monotherapy] in drug naive patients with type 2 [diabetes mellitus]

Trial Profile

A multi-centre, randomised, double-blind active controlled study to compare the effect of 24 weeks treatment with combination therapy of LAF237 [vildagliptin] and pioglitazone to LAF237 monotherapy or pioglitazone monotherapy [monotherapy] in drug naive patients with type 2 [diabetes mellitus]

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2006

At a glance

  • Drugs Pioglitazone; Vildagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top